Once Aryan Skynet Goes Live It Doesn't Matter Who Pulled The Switch
“They are not our friend, believe me,” Donald Trump warned voters about Mexico when he announced his run for the White House. “They’re bringing drugs,” the self-appointed heir to the unenviable Reagan legacy further charged, winning the easy approval of the actors hired to play Trump supporters at the staged event. Trump, as it turns out, however, has no problem with Mexican pharmaceuticals being imported into the United States – as long as cronies are the dealers. The Wall Street Journal reveals:
Donald Trump is going to build a wall, and it’s going to be a beautiful wall, and everyone will love it—but it’s also going to have one notable side entrance. To wit, the GOP frontrunner won’t let Mexicans into America but he’ll make an exception for Mexican drugs.
Mr. Trump released a 10-paragraph health plan last week, perhaps in response to the criticism that he has no policy details. […] one detail that leapt out for comment is his endorsement of foreign pharmaceutical importation […] His campaign promises to “remove barriers to entry into free markets,” because “allowing consumers access to imported, safe and dependable drugs from overseas will bring more options to consumers.”
Sorry, it won’t. The U.S. maintains a “closed” drug distribution network of manufacturers, suppliers and pharmacies—precisely because overseas drugs often aren’t safe and dependable. Recent years have seen a proliferation of pill mills and forgery rings that slip counterfeit or adulterated products into global supply chains. The World Health Organization estimates 10% of drugs world-wide are bogus.
In the case of Mexico, the U.S. State Department warns travellers that as many as 25% of the medications available south of the border are fake. The Los Zetas, Sinaloa and Juárez cartels have diversified their portfolios into deceptive pharmaceuticals. The modern “closed” U.S. system was created in 1999 because Southern California was awash with fraudulent black-market compounds smuggled from Mexico.
Present at that notorious Trump campaign launch at which the current frontrunner made the remarks about Mexican illegals and drugs was pharmaceuticals billionaire and militant Zionist Stewart “Stewie Rah Rah” Rahr, who as Aryan Skynet previously reported, created a website in 2011 to test the waters for a Trump candidacy. Rahr’s Kinray Inc. was acquired in 2010 by medicine giant Cardinal Health, headed by George S. Barrett; but Rahr never lost his interest in the pharaceuticals game. Drug Store News, which interviewed the Zionist billionaire five years ago, offered this:
Could [SAG actor] Donald Trump’s next big role be president of the United States?
More importantly, would Trump the president be good for the country and, more specifically, for retail and wholesale pharmacy?
Stewart Rahr, fresh from the sale of the drug distribution business that propelled him into Trump’s stratospheric income bracket, clearly thinks so. […]
Lately, the self-described “King of all Fun” is focused on what he sees as a high calling: the effort to put Trump into national office. […]
What would a Trump presidency mean for retail and wholesale pharmacy? Rahr asserted the billionaire “would be a great champion for our industry. … He doesn’t like the Obama healthcare plan,” the executive said. “He thinks there’s too many holes in it, it doesn’t take care of everyone and it’s too expensive. As for the pharmaceutical industry, as long as the product is made in America, he’d support it because that creates revenues and employs Americans,” Rahr said. “He’ll be a friend of this industry, as long as it would be made or distributed here in the United States and not elsewhere.”
A Trump presidency also would benefit from its ties to the former Kinray leader, Rahr said. “With [my background in] the pharmaceutical industry, certainly we’d have an ear to explain the problems we have as manufacturers and as distributors, in health care and pharmacies especially. … I am who I am today because of the pharmaceutical business.”
Trump, according to Rahr, would support the pharmaceutical industry “as long as the product is made in America” – a claim that clearly conflicts with Trump’s recently released proposal. Was Rahr, who expresses an interest here in exercising his personal influence over Trump on behalf of fellow drug industry players, the secret mover behind Trump’s plan to “remove barriers to entry into free markets” for cheap Mexican products like the ones imported by Cardinal Health?
The FDA halted Cardinal’s importation of Mexican-manufactured procedure kits in 2011, “saying these kits may have been assembled without adequate documentation [i.e., the kits were wetbacks].” The company also got into trouble through unrestricted online drug-marketing practices alleged to have contributed to rampant painkiller addictions in the U.S. – activities that resulted in Cardinal being targeted for hostile scrutiny more than once by the DEA.
“Cardinal has acquired 18 companies since 2010, including Yong Yu in [Donald Trump’s odious] China,” The Columbus Dispatch reports, and “intends to expand its operations in Canada and Puerto Rico.” Now Cardinal Health is colluding with CVS Caremark to procure even greater quantities of cheap generic drugs in the overseas market for distribution in the United States. The company is also intensifying production of its own products – but less of this will be happening in the United States. In 2013 Cardinal announced it was moving surgical kit production facilities from Waukegan, Illinois, to Mexico.
Humorously, under the Drug Store News article, one finds an obsequious comment left by an employee of Xttrium Laboratories, who heaps praise on both Rahr and Trump, throwing in some shameless 9/11 remembrance in the process. Chicago-based Xttrium, which imports ingredients from Mexico, has a history of shoddy practices, and was censured by the FDA for the “presence of filth” in its facilities and for having adulterated its products “in that they consist in whole or in part of […] filthy, putrid, or decomposed substance.” These products are then distributed by generic specialist Cardinal Health.
“Generics are the wave of the future,” Rahr told a Forbes interviewer a few years ago, “and it’s so important to – to capture that market.” Goldman Sachs upgraded Cardinal Health’s stock rating this week, adding it to the bank’s celebrated Conviction Buy List. Could the Goldman Sachs research team have been influenced in this decision by Trump’s strong showing in the primaries?